Month: November 2018

Axovant Strengthens Team with Additional Expertise to Support Gene Therapy Pipeline

From Startup Axovant Link to Full Article: http://investors.axovant.com/news-releases/news-release-details/axovant-stengthens-team-additional-expertise-support-gene Greg MacMichael, Ph.D., formerly global head of cell and gene therapy technical development and manufacturing at Novartis, joins Axovant as SVP of technical operations Parag Meswani, Pharm.D., formerly head of U.S. marketing and diagnostics at Spark Therapeutics, joins Axovant as SVP of

ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies

From Startup ARQULE Link to Full Article: BURLINGTON, Mass.–(BUSINESS WIRE)–Nov. 29, 2018– ArQule, Inc. (Nasdaq: ARQL) today announced that it will host a call to discuss the updated safety, PK, biomarker and anti-tumor activity data from the company’s Phase 1 dose escalation study in patients with relapsed or refractory hematologic

Calico Announces Collaboration with the University of Pennsylvania for Translational Medicine Efforts in Aging and Age-related Diseases

From Startup Calico Labs Link to Full Article: https://www.calicolabs.com/news/2018/11/28/ Garret FitzGerald to Become Senior Advisor to Calico SOUTH SAN FRANCISCO, Calif, November 28, 2018 – Calico Life Sciences today announced a new collaboration with the University of Pennsylvania’s Institute for Translational Medicine and Therapeutics (ITMAT), led by Dr. Garret FitzGerald,

Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy

From Startup Precision Biosciences Link to Full Article: http://precisionbiosciences.com/precision-biosciences-receives-fda-authorization-to-initiate-clinical-study-of-gene-edited-cancer-immunotherapy/ DURHAM, North Carolina, USA, November 27, 2018 – Precision BioSciences and Servier today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for PBCAR0191, an allogeneic anti-CD19 CAR T therapy for B-cell acute lymphoblastic leukemia

Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors

From Startup Arbutus Bio Link to Full Article: http://investor.arbutusbio.com/news-releases/news-release-details/arbutus-appoints-dr-frank-torti-chairman-its-board-directors WARMINSTER, Pa., Nov. 26, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Frank Torti has been appointed as Chairman of the Company’s Board of Directors, effective November

Axovant Stengthens Team with Additional Expertise to Support Gene Therapy Pipeline

From Startup Axovant Link to Full Article: http://investors.axovant.com/news-releases/news-release-details/axovant-stengthens-team-additional-expertise-support-gene Greg MacMichael, Ph.D., formerly global head of cell and gene therapy technical development and manufacturing at Novartis, joins Axovant as SVP of technical operations Parag Meswani, Pharm.D., formerly head of U.S. marketing and diagnostics at Spark Therapeutics, joins Axovant as SVP of

Magenta Therapeutics to Host Webcast of Investor and Analyst Event During ASH

From Startup Magenta Therapeutics Link to Full Article: https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-host-webcast-investor-and-analyst-event CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 26, 2018– Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that it will host a live webcast of an investor and

Genentech’s Immunology/Infectious Disease Deal Maker On Following The Science

From Startup https://www.microbiotica.com/home Link to Full Article: https://www.microbiotica.com/news/20/58/Genentechs-ImmunologyInfectious-Disease-Deal-Maker-On-Following-The-Science.html Genentech’s infectious diseases and immunology dealmaker speaks to Scrip about the significance of following the science when it comes to partnering. When reflecting on the licensing deals inked this year by biotech behemoth Genentech Inc., two really stand out: the June deal

Heron Therapeutics to Present at the Evercore ISI HealthCONx Conference

From Startup Heron Therapeutics Link to Full Article: https://herontherapeutics.gcs-web.com/news-releases/news-release-details/heron-therapeutics-present-evercore-isi-healthconx-conference SAN DIEGO, Nov. 20, 2018 /PRNewswire/ — Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart,

Synlogic to Webcast Presentation at the 30th Annual Piper Jaffray Healthcare Conference

From Startup Synlogic Tx Link to Full Article: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 20, 2018– Synlogic(Nasdaq:SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the 30th Annual Piper Jaffray Healthcare Conference at 8:30 am ET on Wednesday, November 28, 2018, in